Omeros stock rises in premarket after $36,000-a-vial Yartemlea price is set
Omeros Corp shares were up 0.55, or about 4%, at $14.09 in premarket trade on Thursday after the drugmaker set a $36,000 price for each single-dose vial of its newly approved Yartemlea treatment for transplant-associated thrombotic microangiopathy. “Median utilization was 8 to 10 vials per treatment course,” Chief Executive Gregory Demopulos told analysts. The stock rose 6.6% in extended trade on Wednesday. Reuters